Morgan Stanley’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Morgan Stanley’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$203K	Buy	5,916 +1	+0%	+$34	﹤0.01%	5860
2025 Q4	$195K	Sell	5,915 -1	-0%	-$31	﹤0.01%	5946
2025 Q3	$169K	Hold	5,916	–	–	﹤0.01%	5951
2025 Q2	$152K	Buy	5,916 +1	+0%	+$25	﹤0.01%	5958
2025 Q1	$163K	Sell	5,915 -26	-0.4%	-$720	﹤0.01%	5822
2024 Q4	$160K	Sell	5,941 -1	-0%	-$28	﹤0.01%	5869
2024 Q3	$171K	Buy	5,942 +5,940	+297,000%	+$170K	﹤0.01%	5807
2024 Q2	$56	Hold	2	–	–	﹤0.01%	7462
2024 Q1	$71	Hold	2	–	–	﹤0.01%	7410
2023 Q4	$62	Buy	+2	New	+$50	﹤0.01%	7609
2022 Q1	–	Sell	-600	Closed	-$16K	–	8012
2021 Q4	$16K	Buy	+600	New	+$15.8K	﹤0.01%	7299

Other funds holding FTXH

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $208M AUM 30.96% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return

VCM

Vivaldi Capital Management Chicago, Illinois $723M AUM 30.89% 1-Year Est. Return

Morgan Stanley's FTXH Position: Q1 2026 in Review

Morgan Stanley increased its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 0.02% in Q1 2026, buying an estimated $34 and bringing the position to 5,916 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #5860.

Morgan Stanley first reported a position in FTXH in Q4 2021 and has held it in 11 quarters since. 32 funds tracked by Wall St. Rank hold FTXH as of Q1 2026.

Morgan Stanley held 5,916 shares of First Trust Nasdaq Pharmaceuticals ETF worth $203K as of Q1 2026.
Morgan Stanley bought 1 First Trust Nasdaq Pharmaceuticals ETF share in Q1 2026, an estimated $34.
First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5860 holding.
Morgan Stanley first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2021 and has held it in 11 quarters since.
32 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.